BQST
BioQuest Corp.0.5110
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
15.28MP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
10-Q
Q1 FY2023 results
Bioquest Corp. posted a narrower operating loss of $49,672 for Q1 FY2023 ended July 31, 2022, down from $464,147 a year earlier, thanks to slashed compensation and stock expenses while professional fees ticked up to $47,785. Net loss widened to $123,429 from $437,045, driven by a $50,000 derivative valuation hit that offset the operating gain; interest expense eased to $23,757. Cash dwindled to $14,955 after $18,585 used in operations, with $183,300 in convertible notes in technical default extended to September 30, 2022, via 40,000 shares. No revenue yet, but a June 23, 2022, letter of intent eyes acquiring Progressus Clean Technologies for 90,000,000 shares to pivot into green hydrogen tech. Stockholders' deficit deepened to $536,419. Funding remains elusive.
10-K
FY2022 results
BioQuest Corp. reported no revenue for FY2022 ended April 30, 2022, with operating expenses dropping sharply to $817,920 from $2.2 million in FY2021, yielding a net loss of $821,022 versus $2.3 million last year—driven by a $1.9 million stock settlement of accrued compensation in Q1 FY2022 that cleared liabilities and halted further pay. The remaining three quarters showed minimal activity, with cash burn easing to $116,720 annually from $193,206, ending with $33,540 in cash against $466,530 in liabilities, including defaulted convertible notes. No quarterly breakdowns disclosed, but momentum stalled post-settlement amid a strategic pivot to green energy via a June 2022 LOI for Progressus Clean Technologies. Liquidity hinges on financing; going concern doubts persist. Epidemics like COVID-19 could further disrupt operations.
10-Q
Q3 FY2022 results
Bioquest Corp. posted a rare Q3 profit of $50,094 for the period ended January 31, 2022, swinging from a $667,288 loss a year earlier, thanks to a $50,000 stock compensation reversal and a $1,471 derivative gain that offset $4,098 in interest. Yet nine-month results showed a $574,890 net loss, improved from $1,619,798 last year, driven by lower operating expenses including slashed compensation to zero from $1,024,000. Cash dwindled to $116 amid $65,144 in operating outflows, balanced by $65,000 from stock sales, while liabilities dropped to $393,674 after settling $1,885,873 in accrued pay with 2,514,497 shares. Convertible notes totaling $98,300 loom with 6-10% rates and discounts, but no default yet. Derivative swings narrowed the net loss versus operating by less than 20%. No revenue yet. Internal controls remain weak.
8-K
Auditor switch amid concerns
Bioquest Corp. switched auditors on May 17, 2022, dismissing Haynie & Company after their going-concern modification in the August 13, 2021 report, and appointing L J Soldinger Associates, LLC on May 18 to audit the year ended April 30, 2022. No disagreements or reportable events marred the prior engagement. This change signals fresh oversight amid ongoing viability concerns.
10-Q
Q1 FY2022 results
Bioquest Corp. posted no revenue in Q1 FY2022 ended October 31, 2021, but narrowed its operating loss to $176,633 from $629,173 a year earlier, thanks to slashed compensation costs. Over the six months, the operating loss eased to $640,781 from $950,803 y/y, while net loss improved to $624,984 from $952,511, with the gap to operating loss driven by a $74,045 gain on derivative liability offsetting higher interest expense of $58,248. EPS held at $(0.02) for the quarter on 9,418,007 weighted shares, reconciling cleanly to the net loss. Cash ticked up to $818 on $65,000 from stock sales, funding $64,442 in operating outflows, yet liabilities dropped sharply to $450,507 after settling $1,885,873 in accrued compensation via 2,514,497 shares. Convertible notes of $58,300 linger in default. No non-GAAP metrics disclosed in the 10-Q. Still, persistent funding needs cloud the path ahead.
AIPG
AI TECHNOLOGY GROUP INC
2.50+0.00
BISA
Baltic International USA, Inc.
0.00+0.00
BKHA
Black Hawk Acquisition Corporat
11.25+0.00
BRRN
Born Inc.
0.06+0.00
BSAA
BEST SPAC I Acquisition Corp.
10.10+0.00
BYNO
byNordic Acquisition Corporatio
12.15+0.00
ETHM
Dynamix Corporation
10.40-0.05
GDST
Goldenstone Acquisition Limited
10.20-0.30
QSEA
Quartzsea Acquisition Corporati
10.22+0.00
TNBI
Tanke Biosciences Corp.
0.03+0.00